BioSpace News Archive

The start of summer means more tank tops and shorts, and for some people, a pesky new skin condition they may not have noticed before.

Incyte (Nasdaq:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy.

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company’s First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor

Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire Twistle, Inc.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS).

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the securing of a €11 million non-dilutive loan guaranteed by the French government.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), , today announced the closing of its previously announced registered direct offering to Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock

Aethlon Medical, Inc.Aethlon Medical, Inc., a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported financial results for its fiscal year ended March 31, 2021 and provided an update on recent developments.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 141,800 shares of the Company’s common stock at an exercise price per share of $23.40, which was the closing price on June 23, 2021.

Theravance Biopharma, Inc. announced today that it intends to offer its ordinary shares in an underwritten public offering.